News

LAVA Therapeutics signed agreement with CATO SMS to conduct its Phase I/IIa trial with T-cell engager LAVA-051 in hematologic malignancies

November 24, 2020

Utrecht, the Netherlands & Philadelphia, USA and Schiphol, the Netherlands 24 November 2020 – LAVA Therapeutics (“LAVA”) and CATO SMS...

Read More
News

Double Bond Pharmaceutical concludes Key Opinion Leader (KOL) meeting, an important milestone for SI-053 Phase 1 clinical study

September 29, 2020

Uppsala, Sweden, 28 September 2020 – DBP has recently concluded KOL meeting with Professor Dr. Manfred Westphal (Department of neurosurgery,...

Read More
News

CATO SMS Acquires Array Biostatistics

September 15, 2020

Global Provider Expands Specialized Clinical Research Offering with Enhanced Biostatistical Services CARY, N.C., September 15, 2020 – CATO SMS announced...

Read More
News

CATO SMS Unveils New Brand

September 2, 2020

Cary, N.C.; Sept. 2, 2020 (Business Wire) –  CATO SMS unveiled its new brand today, revealing an updated look and...

Read More
News

Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

May 26, 2020

The aim of the open-label, dose-escalation Phase I/II trial is to evaluate the safety, efficacy and pharmacokinetics of CyPep-1 given...

Read More
News

CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

May 19, 2020

InteRNA is advancing its lead compound INT-1B3 into the clinic. INT-1B3 is a chemically modified miR-193a-3p mimic that holds great...

Read More
News

COVID-19 CATO SMS OPERATIONS UPDATE

March 16, 2020

As the COVID-19 pandemic spreads across the globe, CATO SMS continues to take steps to address the challenges in study...

Read More